Roche Considers Selling Cancer Data Specialist Flatiron Health Business, Highlights Challenges With Start-Up Acquisitions
Roche Considers Selling Cancer Data Specialist Flatiron Health Business, Highlights Challenges With Start-Up Acquisitions
Roche Holding AG (OTC:RHHBY) is reportedly contemplating the divestiture of Flatiron Health, a cancer data specialist Roche acquired in 2018 for $1.9 billion.
罗氏(ADR)正在考虑出售2018年以19亿美元收购的癌症数据专家Flatiron Health。
The move underscores the complexities and potential pitfalls that large pharmaceutical companies encounter when investing in early-stage health technology firms.
此举突显了大型制药公司在投资初期健康科技公司时遇到的复杂性和潜在风险。
Also Read: Roche's New Immunotherapy Fails To Show Benefit Over Merck's Blockbuster Keytruda In Lung Cancer Patients.
此外阅读：罗氏的新免疫疗法未能显示肺癌患者比默克的畅销药Keytruda获益。
Flatiron Health was founded by two former executives from Alphabet Inc's (NASDAQ:GOOG) (NASDAQ:GOOGL) Google.
Flatiron Health由Alphabet Inc（纳斯达克：GOOG）（纳斯达克：GOOGL）谷歌的两名前高管创立。
The company manages electronic patient records for numerous U.S. cancer clinics, boasting one of the most extensive repositories of cancer data.
该公司管理着许多美国癌症诊所的电子病历，拥有最广泛的癌症数据库之一。
The start-up mines this data and sells it to pharmaceutical companies to aid in research and development.
这家初创企业开采这些数据并将其出售给制药公司以协助研究和开发。
Roche's acquisition of Flatiron has not been without its challenges. Despite operating as a separate legal entity, Flatiron's association with Roche has deterred some rival drugmakers from engaging with the start-up, impacting its sales.
罗氏收购Flatiron并非没有遇到挑战。尽管作为独立的法人实体运营，但Flatiron与罗氏的联系已经阻碍了一些竞争对手与该初创企业进行交流，影响其销售。
Flatiron generates approximately two-thirds of its revenue from selling data to pharmaceutical companies, a business model similar to that of Warburg Pincus-backed Modernizing Medicine, which has seen profitable returns for private equity investors.
Flatiron大约有三分之二的营业收入来自向制药公司出售数据的业务模式，这与华尔街重金投资人支持的现代医学类似，他们已经在股权投资方面看到了盈利的回报。
The departure of key Roche executives who initially supported the Flatiron acquisition has left the company with fewer advocates within Roche.
最初支持Flatiron收购的关键罗氏高管的离职已经让该公司的支持者减少。
The Financial Times report adds that Roche is collaborating with Citigroup Inc (NYSE:C) to explore strategic options for Flatiron, including a potential divestiture or partial sale to a partner who can assist in managing the business.
《金融时报》的报道补充称，罗氏正在与花旗集团（纽交所：C）合作，探讨Flatiron的战略选择，包括潜在的剥离或部分出售给能够协助管理业务的合作伙伴。
Despite its financial struggles, Flatiron's data has significantly contributed to Roche's cancer drug development, currently with about 60 oncology drugs in clinical trials.
尽管Flatiron面临着财务困境，但其数据已经极大地促进了罗氏的癌症药物研发，目前该公司正在进行约60个肿瘤领域的临床试验。
The strategic review may not result in Flatiron changing hands, the FT report added.
《金融时报》报道补充称，战略审查可能不会导致Flatiron更换主人。
Last month, Roche announced topline results from two arms of an ongoing multi-part Phase 1 clinical trial for CT-996 for type 2 diabetes and obesity.
上个月，罗氏公布了Ct-996治疗2型糖尿病和肥胖症的多部分Ⅰ期临床试验的上市结果。
The data showed that treatment with CT-996 in participants with obesity and without type 2 diabetes resulted in a clinically meaningful placebo-adjusted mean weight loss of -6.1% within four weeks.
数据显示，Ct-996在没有2型糖尿病的肥胖病人中治疗4周后，平均体重损失较安慰剂组减少了6.1%，属于临床意义上的。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免责声明：本内容部分使用人工智能工具生成，并经Benzinga编辑审核发布。